Freenome, Inc. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect
Freenome, Inc. (FRNM) reported Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect of -$427.66 thousand for the 6-month period ending 2026-06-30, per its S-1 filed 2026-08-18.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect · last filed 2026-08-18
- Freenome, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2026-03-31 was -$297.85K, a 578.45% decline year-over-year.
- Freenome, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2025-03-31 was $62.25K.
- Freenome, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2024-06-30 was $1.29M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 0 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | -$427.66K S-1 · filed 2026-08-18 | ||||
| 2026-03-31 | -$297.85K S-4/A · filed 2026-06-11 | ||||
| 2025-12-31 | -$264.65K S-1 · filed 2026-08-18 | ||||
| 2025-09-30 | $48.23K 10-Q · filed 2025-11-13 | ||||
| 2025-06-30 | $214.72K S-1 · filed 2026-08-18 | ||||
| 2025-03-31 | $62.25K S-4/A · filed 2026-06-11 | ||||
| 2024-12-31 | $1.13M S-1 · filed 2026-08-18 | ||||
| 2024-09-30 | $1.21M 10-Q · filed 2025-11-13 | ||||
| 2024-06-30 | $1.29M 10-Q · filed 2025-08-13 | ||||
| 2024-03-31 | $0.00 10-Q · filed 2025-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| BioNexus Gene Lab Corp (BGLC) | $0.004B | ||
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |